Displaying drugs 8351 - 8375 of 8507 in total
ASI402
ASI402 is a monoclonal antibody that targets an aberrantly glycosylated antigen Mucin 1. It is being investigated in cancers.
Investigational
RAV12
RAV12 is investigated for use/treatment in solid tumors. RAV12 is a solid. RAV12 is a chimeric antibody that recognizes RAAG12, an N-linked carbohydrate antigen found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells.
Investigational
Methopterin
Methopterin is thought to have effects on osteoclasts and to inhibit inflammatory bone destruction.
Investigational
STC3141
STC3141, was investigated in clinical trial NCT04880694 to evaluate its safety and effect in subjects with severe COVID-19 pneumonia.
Investigational
Latiglutenase
Investigational
Fx-1006A
Fx-1006A is a small molecule compound with the potential to treat genetic disorders, such as familial amyloid cardiomyopathy (FAC) and familial amyloid polyneuropathy (FAP).
Investigational
Morphine glucuronide
Investigational
G4460
Investigational
alpha-Conotoxin VC 1.1
Investigational
Vasomera
Investigational
Elvucitabine
Investigational
Dociparstat sodium
Investigational
CPI-006
CPI-006 was investigated in clinical trials NCT03454451, NCT04464395, and NCT04734873 to evaluate its safety and efficacy. NCT03454451 focused on advanced cancers (e.g., non-small cell lung cancer, renal cell cancer, colorectal cancer). NCT04464395 and NCT04734873 assessed its use for hospitalized COVID-19 patients alone or with standard care.
Investigational
R343
R343, was investigated in clinical trial NCT01591044 to evaluate its safety and efficacy in patients with mild to moderate asthma.
Investigational
ENMD-1198
Investigational
ARQ 171
Investigational
TAS-108
Investigational
Epothilone D
Investigational
XC221
XC221 was investigated in clinical trials to treat patients with respiratory infections, including influenza, COVID-19, and other acute viral upper respiratory infections.
Investigational
Annamycin
Investigational
FT516
FT516 is an investigational and engineered off-the-shelf natural killer (NK) cell therapy originating from induced pluripotent stem cells (iPSC). This compound expresses a high-affinity 158V, CD16 (hnCD16) Fc receptor that has an enhanced binding ability to tumor-targeting antibodies, and is resistant to downregulation. FT516 is currently being tested against acute...
Investigational
PPI-1019
Apan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.
Investigational
Refametinib
Investigational
Displaying drugs 8351 - 8375 of 8507 in total